Pharmaceuticals Global On demand · 24-48h

Global Neuropathic Pain Market Strategic Research Report

$3,500 USD

Strategic Research Report

Global Neuropathic Pain Market

Market Research Reports · Global

Market Research Reports Intelligence Series

By Type: Anticonvulsants, Serotonin and Norepinephrine Reuptake Inhibitors, Tricyclic Antidepressant, Opioids, Topical Agents, Other Classes

By Application: Diabetic Peripheral Neuropathy, Postherpetic Neuralgia, Chemotherapy-Induced Peripheral Neuropathy, Trigeminal Neuralgia, HIV-Associated Neuropathy, Phantom Limb Pain, Others (MS, Spinal Cord Injury)

Key Players: Pfizer Inc., GlaxoSmithKline plc, Eli Lilly and Company, Johnson & Johnson Services, Inc., Novartis AG, Teva Pharmaceutical Industries Ltd., Grünenthal GmbH, UCB S.A., Sanofi S.A., Biogen Inc., Astellas Pharma Inc., Vertex Pharmaceuticals Incorporated, Aptinyx Inc., Daiichi Sankyo Company, Limited, Takeda Pharmaceutical Company Limited, Bayer AG, Mallinckrodt Pharmaceuticals, Sun Pharmaceutical Industries Ltd., Assertio Holdings, Inc., Ipsen S.A., Endo International plc, Lexicon Pharmaceuticals, Inc.

Region: Global

Formats: PDF, Excel, Word & PowerPoint

Base year: 2024 · forecast to 2032

Length: 150 pages

Overview

Scope of the Report

Anyone assessing the global Neuropathic Pain market will find its scope, segmentation, regional coverage and competitive analysis laid out in this report, together with the risks and sensitivities behind the outlook.

Analysis starts from a global definition of the market, then moves to segment-level outlooks by type and application, and finishes with regional and country-level forecasts.

Market Segmentation

The Neuropathic Pain market is segmented along the following dimensions, each assessed on its own growth outlook:

By Drug Class: Anticonvulsants, Serotonin and Norepinephrine Reuptake Inhibitors, Tricyclic Antidepressant, Opioids, Topical Agents and Other Classes
By Indication: Diabetic Peripheral Neuropathy, Postherpetic Neuralgia, Chemotherapy-Induced Peripheral Neuropathy, Trigeminal Neuralgia, HIV-Associated Neuropathy, Phantom Limb Pain and Others (MS, Spinal Cord Injury)
By Route of Administration: Oral, Topical and Parenteral
By Distribution Channel: Hospital Pharmacies, Retail Pharmacies and Online Pharmacies

Regional analysis covers Asia Pacific, North America, Europe, the Middle East and Africa and Latin America, with country-level forecasts.

Market Context

In pharmaceuticals, development pipelines, clinical guidelines and payer attitudes commonly decide which products and companies gain ground. In a market such as Neuropathic Pain, competition typically depends on product or service quality, price positioning, distribution reach and the ability to meet evolving customer requirements.

Competitive Landscape

22 companies are profiled in the report: Pfizer Inc., GlaxoSmithKline plc, Eli Lilly and Company, Johnson & Johnson Services, Inc., Novartis AG, Teva Pharmaceutical Industries Ltd., Grünenthal GmbH, UCB S.A., Sanofi S.A., Biogen Inc., Astellas Pharma Inc., Vertex Pharmaceuticals Incorporated, Aptinyx Inc., Daiichi Sankyo Company, Limited, Takeda Pharmaceutical Company Limited, Bayer AG, Mallinckrodt Pharmaceuticals, Sun Pharmaceutical Industries Ltd., Assertio Holdings, Inc., Ipsen S.A., Endo International plc and Lexicon Pharmaceuticals, Inc..

Each profile reviews the company's overview, key products and segments, financial performance, business strategy and SWOT, with strategic implications for 2026 to 2032.

What the Report Covers

Its chapters cover:

Market definition and scope for Neuropathic Pain, with the market size and growth forecast for 2026 to 2032
Segment outlook by type and by application
Forecasts for Asia Pacific, North America, Europe, the Middle East and Africa and Latin America, plus 22 individual countries
Growth drivers and inhibitors, with an assessment of how strongly each affects the outlook
Company profiles and the competitive landscape, including competitive intensity and key player strategies
Structural analysis using the Porter's Five Forces, PESTLE and SWOT frameworks
Future trends, technology and innovation, and the investment and M&A outlook

The report is produced on demand to the scope described here and delivered in PDF within 24 to 48 hours of purchase.

Key Questions Answered

How large is the global Neuropathic Pain market today, and how is it expected to grow between 2026 and 2032?
What is driving demand for Neuropathic Pain, and what could slow growth?
Which drug class segments of Neuropathic Pain - Anticonvulsants, Serotonin and Norepinephrine Reuptake Inhibitors and Tricyclic Antidepressant - are positioned for the strongest growth?
How does the Neuropathic Pain market differ by route of administration (Oral, Topical and Parenteral)?
How does the Neuropathic Pain market differ by distribution channel (Hospital Pharmacies, Retail Pharmacies and Online Pharmacies)?
How might new entrants and substitutes change competition in Neuropathic Pain?

Who Can Use This Report

Companies active in Neuropathic Pain benchmarking their position and planning product, capacity and go-to-market strategy
Customers, distributors and channel partners such as Diabetic Peripheral Neuropathy, Postherpetic Neuralgia and Chemotherapy-Induced Peripheral Neuropathy evaluating demand and sourcing options
Investors, financial analysts and consultants assessing growth opportunities, competitive dynamics and M&A potential
Associations, public bodies and academic or research teams following sector developments

Segments covered in this report

By Type

AnticonvulsantsSerotonin and Norepinephrine Reuptake InhibitorsTricyclic AntidepressantOpioidsTopical AgentsOther Classes

By Application

Diabetic Peripheral NeuropathyPostherpetic NeuralgiaChemotherapy-Induced Peripheral NeuropathyTrigeminal NeuralgiaHIV-Associated NeuropathyPhantom Limb PainOthers (MSSpinal Cord Injury)

Click a chapter to expand

01Executive Summary

02Industry Overview & Forecast

2.1.1 Market Definition and Scope
2.1.2 Market Size and Growth Forecast
2.1.3 Segment Outlook by Drug Class
2.1.4 Segment Outlook by Indication
2.1.5 Segment Outlook by Route of Administration
2.1.6 Regional Outlook
2.1.7 Structural Developments Shaping the Forecast
2.1.8 Forecast Risks and Sensitivities

03Market Segmentation by Drug Class

3.1 Market Segmentation by Drug Class
3.1.1 Market by Drug Class Overview
3.1.2 Anticonvulsants
3.1.3 Serotonin and Norepinephrine Reuptake Inhibitors
3.1.4 Tricyclic Antidepressant
3.1.5 Opioids
3.1.6 Topical Agents
3.1.7 Other Classes

04Market Segmentation by Indication

4.1 Market Segmentation by Indication
4.1.1 Market by Indication Overview
4.1.2 Diabetic Peripheral Neuropathy
4.1.3 Postherpetic Neuralgia
4.1.4 Chemotherapy-Induced Peripheral Neuropathy
4.1.5 Trigeminal Neuralgia
4.1.6 HIV-Associated Neuropathy
4.1.7 Phantom Limb Pain
4.1.8 Others (MS, Spinal Cord Injury)

05Market Segmentation by Route of Administration

5.1 Market Segmentation by Route of Administration
5.1.1 Market by Route of Administration Overview
5.1.2 Oral
5.1.3 Topical
5.1.4 Parenteral

06Market Segmentation by Distribution Channel

6.1 Market Segmentation by Distribution Channel
6.1.1 Market by Distribution Channel Overview
6.1.2 Hospital Pharmacies
6.1.3 Retail Pharmacies
6.1.4 Online Pharmacies

07Regional Market Forecast

Asia Pacific
North America
Europe
Middle East & Africa
Latin America

08Country-Level Market Forecast

8.1 Asia Pacific
8.1.1 China
8.1.2 Japan
8.1.3 India
8.1.4 Australia
8.1.5 South Korea
8.1.6 Rest of Asia Pacific
8.2 North America
8.2.1 United States
8.2.2 Canada
8.2.3 Mexico
8.2.4 Rest of North America
8.3 Europe
8.3.1 United Kingdom
8.3.2 Germany
8.3.3 France
8.3.4 Italy
8.3.5 Spain
8.3.6 Rest of Europe
8.4 Middle East & Africa
8.4.1 GCC
8.4.2 South Africa
8.4.3 Rest of Middle East & Africa
8.5 Latin America
8.5.1 Brazil
8.5.2 Argentina
8.5.3 Rest of Latin America

09Growth Drivers & Inhibitors

9.1 Growth Drivers & Inhibitors
9.1.1 Section Overview
9.1.2 Growth Drivers
9.1.3 Growth Inhibitors
9.1.4 Driver and Inhibitor Impact Assessment
9.1.5 Analyst Perspective

10Key Company Profiles

10.1 Pfizer Inc.
10.1.1 Company Overview
10.1.2 Key Products & Segments
10.1.3 Financial Performance (2023–2025)
10.1.4 Business Strategy
10.1.5 SWOT Analysis
10.1.6 Strategic Implications (2026–2032)
10.2 GlaxoSmithKline plc
10.2.1 Company Overview
10.2.2 Key Products & Segments
10.2.3 Financial Performance (2023–2025)
10.2.4 Business Strategy
10.2.5 SWOT Analysis
10.2.6 Strategic Implications (2026–2032)
10.3 Eli Lilly and Company
10.3.1 Company Overview
10.3.2 Key Products & Segments
10.3.3 Financial Performance (2023–2025)
10.3.4 Business Strategy
10.3.5 SWOT Analysis
10.3.6 Strategic Implications (2026–2032)
10.4 Johnson & Johnson Services, Inc.
10.4.1 Company Overview
10.4.2 Key Products & Segments
10.4.3 Financial Performance (2023–2025)
10.4.4 Business Strategy
10.4.5 SWOT Analysis
10.4.6 Strategic Implications (2026–2032)
10.5 Novartis AG
10.5.1 Company Overview
10.5.2 Key Products & Segments
10.5.3 Financial Performance (2023–2025)
10.5.4 Business Strategy
10.5.5 SWOT Analysis
10.5.6 Strategic Implications (2026–2032)
10.6 Teva Pharmaceutical Industries Ltd.
10.6.1 Company Overview
10.6.2 Key Products & Segments
10.6.3 Financial Performance (2023–2025)
10.6.4 Business Strategy
10.6.5 SWOT Analysis
10.6.6 Strategic Implications (2026–2032)
10.7 Grünenthal GmbH
10.7.1 Company Overview
10.7.2 Key Products & Segments
10.7.3 Financial Performance (2023–2025)
10.7.4 Business Strategy
10.7.5 SWOT Analysis
10.7.6 Strategic Implications (2026–2032)
10.8 UCB S.A.
10.8.1 Company Overview
10.8.2 Key Products & Segments
10.8.3 Financial Performance (2023–2025)
10.8.4 Business Strategy
10.8.5 SWOT Analysis
10.8.6 Strategic Implications (2026–2032)
10.9 Sanofi S.A.
10.9.1 Company Overview
10.9.2 Key Products & Segments
10.9.3 Financial Performance (2023–2025)
10.9.4 Business Strategy
10.9.5 SWOT Analysis
10.9.6 Strategic Implications (2026–2032)
10.10 Biogen Inc.
10.10.1 Company Overview
10.10.2 Key Products & Segments
10.10.3 Financial Performance (2023–2025)
10.10.4 Business Strategy
10.10.5 SWOT Analysis
10.10.6 Strategic Implications (2026–2032)
10.11 Astellas Pharma Inc.
10.11.1 Company Overview
10.11.2 Key Products & Segments
10.11.3 Financial Performance (2023–2025)
10.11.4 Business Strategy
10.11.5 SWOT Analysis
10.11.6 Strategic Implications (2026–2032)
10.12 Vertex Pharmaceuticals Incorporated
10.12.1 Company Overview
10.12.2 Key Products & Segments
10.12.3 Financial Performance (2023–2025)
10.12.4 Business Strategy
10.12.5 SWOT Analysis
10.12.6 Strategic Implications (2026–2032)
10.13 Aptinyx Inc.
10.13.1 Company Overview
10.13.2 Key Products & Segments
10.13.3 Financial Performance (2023–2025)
10.13.4 Business Strategy
10.13.5 SWOT Analysis
10.13.6 Strategic Implications (2026–2032)
10.14 Daiichi Sankyo Company, Limited
10.14.1 Company Overview
10.14.2 Key Products & Segments
10.14.3 Financial Performance (2023–2025)
10.14.4 Business Strategy
10.14.5 SWOT Analysis
10.14.6 Strategic Implications (2026–2032)
10.15 Takeda Pharmaceutical Company Limited
10.15.1 Company Overview
10.15.2 Key Products & Segments
10.15.3 Financial Performance (2023–2025)
10.15.4 Business Strategy
10.15.5 SWOT Analysis
10.15.6 Strategic Implications (2026–2032)
10.16 Bayer AG
10.16.1 Company Overview
10.16.2 Key Products & Segments
10.16.3 Financial Performance (2023–2025)
10.16.4 Business Strategy
10.16.5 SWOT Analysis
10.16.6 Strategic Implications (2026–2032)
10.17 Mallinckrodt Pharmaceuticals
10.17.1 Company Overview
10.17.2 Key Products & Segments
10.17.3 Financial Performance (2023–2025)
10.17.4 Business Strategy
10.17.5 SWOT Analysis
10.17.6 Strategic Implications (2026–2032)
10.18 Sun Pharmaceutical Industries Ltd.
10.18.1 Company Overview
10.18.2 Key Products & Segments
10.18.3 Financial Performance (2023–2025)
10.18.4 Business Strategy
10.18.5 SWOT Analysis
10.18.6 Strategic Implications (2026–2032)
10.19 Assertio Holdings, Inc.
10.19.1 Company Overview
10.19.2 Key Products & Segments
10.19.3 Financial Performance (2023–2025)
10.19.4 Business Strategy
10.19.5 SWOT Analysis
10.19.6 Strategic Implications (2026–2032)
10.20 Ipsen S.A.
10.20.1 Company Overview
10.20.2 Key Products & Segments
10.20.3 Financial Performance (2023–2025)
10.20.4 Business Strategy
10.20.5 SWOT Analysis
10.20.6 Strategic Implications (2026–2032)
10.21 Endo International plc
10.21.1 Company Overview
10.21.2 Key Products & Segments
10.21.3 Financial Performance (2023–2025)
10.21.4 Business Strategy
10.21.5 SWOT Analysis
10.21.6 Strategic Implications (2026–2032)
10.22 Lexicon Pharmaceuticals, Inc.
10.22.1 Company Overview
10.22.2 Key Products & Segments
10.22.3 Financial Performance (2023–2025)
10.22.4 Business Strategy
10.22.5 SWOT Analysis
10.22.6 Strategic Implications (2026–2032)

11Competitive Landscape

11.1 Competitive Landscape Overview
11.2 Competitive Intensity Assessment
11.3 Key Player Strategies & Positioning
11.4 Competitive Dynamics & Strategic Outlook
11.4.1 Emerging Competitive Threats
11.4.2 Consolidation vs. Fragmentation Outlook
11.4.3 Competitive Response Matrix
11.4.4 Strategic Recommendations, 2026–2032

12Porter's Five Forces Analysis

12.1 Threat of New Entrants
12.2 Bargaining Power of Buyers
12.3 Bargaining Power of Suppliers
12.4 Threat of Substitutes
12.5 Competitive Rivalry

13PESTLE Analysis

13.1 Political
13.2 Economic
13.3 Social and Demographic
13.4 Technological
13.5 Legal and Regulatory
13.6 Environmental
13.7 Strategic Implications of the PESTLE Assessment

14SWOT Analysis

15Future Trends & Outlook

15.1 Future Trends & Outlook
15.1.1 Trend Summary and Commercial Maturity Assessment
15.1.2 Technology and Innovation Trends
15.1.3 Long-Term Market Outlook
15.1.4 Investment & M&A Activity Outlook
15.1.5 Overall Outlook Assessment

Frequently asked questions

Which regions and countries are covered for Neuropathic Pain?

The market is analysed across Asia Pacific, North America, Europe, Middle East & Africa and Latin America, with 22 country-level markets including China, Japan, United States, Canada, United Kingdom, Germany, GCC and South Africa.

What are the main segments of the Neuropathic Pain market?

The market is segmented by Drug Class (Anticonvulsants, Serotonin and Norepinephrine Reuptake Inhibitors, Tricyclic Antidepressant, Opioids, Topical Agents and Other Classes), Indication (Diabetic Peripheral Neuropathy, Postherpetic Neuralgia, Chemotherapy-Induced Peripheral Neuropathy, Trigeminal Neuralgia, HIV-Associated Neuropathy, Phantom Limb Pain and 1 more), Route of Administration (Oral, Topical and Parenteral) and Distribution Channel (Hospital Pharmacies, Retail Pharmacies and Online Pharmacies), with forecasts for each segment.

Which companies are profiled in the Neuropathic Pain market report?

Key players profiled include Pfizer, GlaxoSmithKline plc, Eli Lilly and Company, Johnson & Johnson Services, Novartis AG, Teva Pharmaceutical Industries, Grünenthal GmbH, UCB S.A., Sanofi S.A., Biogen and 12 more, among 22 companies covered in total.

Who should buy the Neuropathic Pain market report?

The report is intended for manufacturers and solution providers, distributors and end users, investors and consultants, and government or industry bodies who need market size, segmentation, competitive and regional data for the Neuropathic Pain market.

What license options are available for this report?

The report is available as a Single User License (US$ 3,500, one named user), a Site License (US$ 5,250, up to 10 users) and a Global / Corporate License (US$ 7,000, unlimited users), all delivered in PDF format.

Research Methodology

All MarketResearchReports.com strategic research reports follow a rigorous, multi-stage methodology combining AI-assisted data synthesis with expert analyst validation.

Secondary Research & Data Aggregation

Systematic collection from 500+ verified sources including SEC filings, industry databases (Bloomberg, Statista, OECD), regulatory filings, trade publications, patent databases, and company annual reports. AI-assisted extraction identifies relevant data points across 10,000+ documents per report.

Market Sizing — Bottom-Up & Top-Down

Dual-validation approach: bottom-up sizing aggregates segment-level production, consumption, and trade data; top-down sizing cross-validates against macroeconomic indicators and total addressable market estimates. Discrepancies >5% trigger analyst review.

Competitive Intelligence

Company profiles built from public financial disclosures, product launches, M&A activity, job postings (as capability proxies), and supply chain mapping. Market share estimates triangulated across revenue, capacity, and shipment data.

Demand Forecasting

CAGR projections use time-series regression on 5-10 years of historical data, adjusted for identified demand drivers (technology adoption curves, regulatory catalysts, demographic shifts) and demand inhibitors (cost barriers, substitution risk). Scenario modeling covers base, optimistic, and conservative cases.

Analyst Validation & Quality Assurance

All quantitative outputs reviewed by a domain-specialist analyst before publication. Data triangulation requires minimum 3 independent sources for every key figure. Reports undergo a structured peer review against our 47-point quality checklist covering methodology, data citations, logical consistency, and formatting standards.

Continuous Updates

On-demand reports are generated at time of purchase, incorporating the most recent available data. Static reports are republished when underlying market conditions shift by >10% from baseline assumptions. Purchasers receive update notifications for 12 months.

PURCHASE THIS REPORT

from $3,500.00

Optional add-ons

Word Document (DOCX) +$500 PowerPoint Slides +$500 Excel Data Sheet +$500 Language Translation +$750

On demand · delivered within 24-48 hours

Secure checkout · SSL encrypted

License terms included

Post-purchase analyst support

Custom research

Need a customized version?

Get country-, segment- or company-specific intelligence tailored to your exact requirements.

Request custom research →

Talk to a research advisor USA: +1-302-703-9904 India: +91-8762746600

Global Neuropathic Pain Market Strategic Research Report

Overview

Scope of the Report

Market Segmentation

Market Context

Competitive Landscape

What the Report Covers

Key Questions Answered

Who Can Use This Report

Segments covered in this report

Table of contents

Frequently asked questions

Research Methodology

Need a customized version?

Leading Brands in This Industry

Global Neuropathic Pain Market Strategic Research Report

Overview

Scope of the Report

Market Segmentation

Market Context

Competitive Landscape

What the Report Covers

Key Questions Answered

Who Can Use This Report

Segments covered in this report

Table of contents

Frequently asked questions

Research Methodology

Related reports

Global Peptide Market Strategic Intelligence Suite

Global Oncology Market Strategic Research Report

Global Peptide Therapy Market Strategic Research Report

Need a customized version?

Leading Brands in This Industry